These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35401381)

  • 1. CEO Regulatory Focus, Analysts' Optimism Bias, and Firm Strategic Change: Evidence From Chinese-Listed Companies.
    Huang C; Zheng W
    Front Psychol; 2022; 13():813920. PubMed ID: 35401381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CEO successor origins, top management team faultline, and strategic change-empirical evidence from China.
    Ren D; Jiang H; Cheng J; Peng C; Zou Y
    Heliyon; 2023 Sep; 9(9):e19200. PubMed ID: 37662732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Relationship Between CEO Duality and Business Firms' Performance: The Moderating Role of Firm Size and Corporate Social Responsibility.
    Mubeen R; Han D; Abbas J; Álvarez-Otero S; Sial MS
    Front Psychol; 2021; 12():669715. PubMed ID: 35035363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of CEO Narcissism and Corporate R&D Investment.
    Wang L; Li H; Mu Y
    Front Psychol; 2022; 13():888618. PubMed ID: 35645881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Female CEO succession and corporate social disclosure in China: unveiling the significance of ownership status and firm performance.
    Shaheen R; Luo Q; Bala H
    Environ Sci Pollut Res Int; 2023 Feb; 30(6):14223-14239. PubMed ID: 36149559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Mechanisms of Chief Executive Officer Characteristics and Corporate Social Responsibility Reporting: Evidence From Chinese-Listed Firms.
    Zhao X; Wang M; Zhan X; Liu Y
    Front Psychol; 2022; 13():794258. PubMed ID: 35401325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEO Overconfidence, Corporate Governance, and R&D Smoothing in Technology-Based Entrepreneurial Firms.
    Huang Y; Wang X; Li Y; Yu X
    Front Psychol; 2022; 13():944117. PubMed ID: 35910989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEO-TMT overseas experience differences and firm performance: A self-categorization theory perspective.
    Xu Z
    Heliyon; 2023 Jul; 9(7):e17845. PubMed ID: 37539289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does corporate governance affect financial analysts' stock recommendations, target prices accuracy and earnings forecast characteristics? An empirical investigation of US companies.
    Bouteska A; Mili M
    Empir Econ; 2022; 63(4):2125-2171. PubMed ID: 36118292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How does CEO narcissism affect enterprise ambidextrous technological innovation? The mediating role of corporate social responsibility.
    Wang Z; Hu X; Yu F
    PLoS One; 2023; 18(1):e0280758. PubMed ID: 36662757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burden or Blessing? CEO Early-Life Adversity Experience and Firm Internationalization Performance.
    Zhou P; Zhao Y; Zhao K
    Front Psychol; 2022; 13():855316. PubMed ID: 35592170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of sustainability integration into the corporate strategy - A perspective on analysts' perceptions and buy recommendations.
    Thun TW; Schneider A; Kayser C; Zülch H
    Heliyon; 2024 Feb; 10(3):e25008. PubMed ID: 38317958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do Returnee Executives Value Corporate Philanthropy? Evidence from China.
    Zhang L; Xu Y; Chen H
    J Bus Ethics; 2022; 179(2):411-430. PubMed ID: 34177016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of CEO Identity on Non-family Managers' Pay Dispersion in Family Firms: A Social Comparison Perspective.
    Zhang W; Chen L; Zhu JA
    Front Psychol; 2021; 12():683011. PubMed ID: 34659004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celebrity CEOs and firm innovation investment: Evidence from Chinese-listed companies.
    Shao D; Lv K; Zhao S; Wang S
    Front Psychol; 2022; 13():978946. PubMed ID: 36478933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEO turnover and corporate innovation: What can we learn from Chinese listed companies.
    Sun S; Jiang H
    Front Psychol; 2022; 13():874907. PubMed ID: 35936347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does CEO tenure moderate the link between corporate social responsibility and business performance in small- and medium-sized enterprises?
    Lee SM; Sinha PN; Bae JE; Lee YK
    Front Psychol; 2022; 13():1037245. PubMed ID: 36562052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do financial performance and firm's value affect the quality of corporate social responsibility disclosure: Moderating role of chief executive officer's power in China.
    Na C; Tian G; Rauf F; Naveed K
    Front Psychol; 2022; 13():925323. PubMed ID: 36059787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEO birth order and corporate social responsibility behaviors: The moderating effect of female sibling and age gap.
    Zheng M; Ren G; Wu S; Jiang Z
    Front Psychol; 2022; 13():1003704. PubMed ID: 36405214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chief Executive Officers Entrepreneurial Orientation, Dynamic Capabilities, and Firm Performance: The Moderating Effect of the Manufacturing Industry.
    Liu Y; Xi M; Jia Y; Geng X
    Front Psychol; 2021; 12():707971. PubMed ID: 34630214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.